




RealRate

PHARMACEUTICAL 2021

Evoked Pharma Inc
Rank 349 of 409



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



RealRate

PHARMACEUTICAL 2021

Evoke Pharma Inc
Rank 349 of 409



The relative strengths and weaknesses of Evoke Pharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Evoke Pharma Inc compared to the market average is the variable Liabilities, Non-Current, increasing the Economic Capital Ratio by 57% points. The greatest weakness of Evoke Pharma Inc is the variable Net Income, reducing the Economic Capital Ratio by 217% points.

The company's Economic Capital Ratio, given in the ranking table, is -516%, being 161% points below the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	9,281
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,536
Liabilities, Non-Current	5,113
Other Assets	153
Other Compr. Net Income	0
Other Expenses	87
Other Liabilities	0
Other Net Income	-107
Property and Equipment	0
Research and Development	6,555
Revenues	23
Selling, General and Administrative Expense	6,429

Output Variable	Value in 1000 USD
Assets	9,434
Liabilities	12,649
Expenses	13,070
Stockholders Equity	-3,215
Net Income	-13,155
Comprehensive Net Income	-13,155
Economic Capital Ratio	-516%



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai